Molecular mechanisms of liver carcinogenesis related to metabolic syndrome

Abstract

Global prevalence of non-alcoholic fatty liver disease (NAFLD) and of NAFLD-hepatocellular carcinoma (HCC) is estimated to grow in the next years. The burden of NAFLD and the evidence that NAFLD-HCC arises also in non-cirrhotic patients, explain the urgent need of a better characterization of the molecular mechanisms involved in NAFLD progression. Obesity and diabetes cause a chronic inflammatory state which favors changes in serum cytokines and adipokines, an increase in oxidative stress, DNA damage, and the activation of multiple signaling pathways involved in cell proliferation. Moreover, a role in promoting NAFLD-HCC has been highlighted in the innate and adaptive immune system, dysbiosis, and alterations in bile acids metabolism. Several dietary, genetic, or combined mouse models have been used to study nonalcoholic steatohepatitis (NASH) development and its progression to HCC, but models that fully recapitulate the biological and prognostic features of human NASH are still lacking. In humans, four single nucleotide polymorphisms (PNPLA3, TM6SF2, GCKR, and MBOAT7) have been linked to the development of both NASH and HCC in cirrhotic and non-cirrhotic patients, whereas HSD17B13 polymorphism has a protective effect. In addition, higher rates of somatic ACVR2A mutations and a novel mutational signature have been recently discovered in NASH-HCC patients. The knowledge of the molecular pathogenesis of NAFLD-HCC will be helpful to personalized screening programs and allow for primary and secondary chemopreventive treatments for NAFLD patients who are more likely to progress to HCC.

Keywords

Hepatocellular carcinoma / mouse model / genetic predisposition / cirrhosis / non-alcoholic fatty liver disease / immune system

References

[1] Younossi ZM,Lim JK.AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review.Gastroenterology2021;160:912-8

[2] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[3] Younossi ZM.Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.JHEP Rep2021;3:100305 PMCID:PMC8215299

[4] Huang DQ,Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2021;18:223-38 PMCID:PMC8016738

[5] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[6] Nahon P,Nault JC.Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma.Hepat Oncol2020;7:HEP36 PMCID:PMC7907968

[7] Eslam M,Romeo S.Genetics and epigenetics of NAFLD and NASH: Clinical impact.J Hepatol2018;68:268-79

[8] Huang Y,Hobbs HH.Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.J Biol Chem2011;286:37085-93 PMCID:PMC3199456

[9] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5 PMCID:PMC2597056

[10] BasuRay S,Smagris E,Hobbs HH.Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis.Proc Natl Acad Sci U S A2019;116:9521-6 PMCID:PMC6511016

[11] He S,Li JZ.A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.J Biol Chem2010;285:6706-15 PMCID:PMC2825465

[12] Pirazzi C,Burza MA.Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.J Hepatol2012;57:1276-82

[13] Yuan X,Perry JR.Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.Am J Hum Genet2008;83:520-8 PMCID:PMC2561937

[14] Speliotes EK,Palmer CD,Hirschhorn JN.GIANT Consortium, MIGen Consortium, NASH CRNPNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.Hepatology2010;52:904-12 PMCID:PMC3070300

[15] Rotman Y,Zmuda JM,Liang TJ.NASH CRNThe association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.Hepatology2010;52:894-903 PMCID:PMC2932770

[16] Sookoian S.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.Hepatology2011;53:1883-94

[17] Salameh H,Masadeh M.PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum.J Clin Transl Hepatol2016;4:175-91 PMCID:PMC5075002

[18] Falleti E,Cmet S.PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.Liver Int2011;31:1137-43

[19] Trépo E,Bontempi G.Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data.Hepatology2014;59:2170-7

[20] Burza MA,Maglio C.PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals.Dig Liver Dis2012;44:1037-41

[21] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol2014;61:75-81

[22] Seko Y,Tanaka S.Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression.Hepatol Res2017;47:1083-92

[23] Kozlitina J,Stender S.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2014;46:352-6 PMCID:PMC3969786

[24] Prill S,Baselli G.The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.Sci Rep2019;9:11585 PMCID:PMC6690969

[25] Dongiovanni P,Maglio C.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology2015;61:506-14

[26] Newberry EP,Xie Y.Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer.Hepatology2021;74:1203-19 PMCID:PMC8390580

[27] Yang J,Nahon P.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer2019;144:533-44

[28] Liu YL,Burt AD.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun2014;5:4309 PMCID:PMC4279183

[29] Tanaka Y,Caddeo A.LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.Gut2021;70:180-93 PMCID:PMC7788230

[30] Meroni M,Fracanzani AL.MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.EBioMedicine2020;57:102866 PMCID:PMC7339032

[31] Buch S,Trépo E.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.Nat Genet2015;47:1443-8

[32] Freund C,Begli NH.The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis.Clin Res Hepatol Gastroenterol2020;44:646-52

[33] Thabet K,Petta S.The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.Hepatology2017;65:1840-50

[34] Donati B,Romeo S.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Sci Rep2017;7:4492 PMCID:PMC5495751

[35] Teo K,Adams L.EU-PNAFLD Investigators, GOLD Consortiumrs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis.J Hepatol2021;74:20-30 PMCID:PMC7755037

[36] Abul-Husn NS,Li AH.A protein-truncating HSD17B13 variant and protection from chronic liver disease.N Engl J Med2018;378:1096-106 PMCID:PMC6668033

[37] Pirola CJ,Flichman D.Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.J Lipid Res2019;60:176-85 PMCID:PMC6314267

[38] Stickel F,Buch S.Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.Hepatology2020;72:88-102

[39] Kozlitina J,Hobbs HH.HSD17B13 and chronic liver disease in blacks and hispanics.N Engl J Med2018;379:1876-7

[40] Santoro N,Zhao H.Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.Hepatology2012;55:781-9 PMCID:PMC3288435

[41] Petta S,Bugianesi E.Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease.PLoS One2014;9:e87523 PMCID:PMC3911959

[42] Meroni M,Paolini E.The rs599839 A>G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients.Cancers (Basel)2021;13:1783 PMCID:PMC8068289

[43] Pelusi S,Pietrelli A.Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease.Sci Rep2019;9:3682 PMCID:PMC6403344

[44] Margini C.The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.Liver Int2016;36:317-24

[45] Kanwal F,Li L.Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease.Hepatology2020;71:808-19

[46] Simon TG,Chong DQ.Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies.Hepatology2018;67:1797-806 PMCID:PMC5906170

[47] Kucukoglu O,Mazzolini GD,Canbay A.Hepatokines and adipokines in NASH-related hepatocellular carcinoma.J Hepatol2021;74:442-57

[48] Grohmann M,Dodd GT.Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC.Cell2018;175:1289-1306.e20 PMCID:PMC6242467

[49] Bonefeld K.Insulin-like growth factor-I and the liver.Liver Int2011;31:911-9

[50] Allaire M.Type 2 diabetes-associated hepatocellular carcinoma: a molecular profile.Clin Liver Dis (Hoboken)2016;8:53-8 PMCID:PMC6490195

[51] Sutti S.Adaptive immunity: an emerging player in the progression of NAFLD.Nat Rev Gastroenterol Hepatol2020;17:81-92 PMCID:PMC7222953

[52] Pfister D,Pinyol R.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Nature2021;592:450-6 PMCID:PMC8046670

[53] van der Windt DJ,Zhang H.Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis.Hepatology2018;68:1347-60 PMCID:PMC6173613

[54] Shalapour S,Bastian IN.Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.Nature2017;551:340-5 PMCID:PMC5884449

[55] Malehmir M,Gallage S.Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.Nat Med2019;25:641-55

[56] Simon TG,Ludvigsson JF.Association between aspirin use and risk of hepatocellular carcinoma.JAMA Oncol2018;4:1683-90 PMCID:PMC6440745

[57] Simon TG,Aleman S,Chan AT.Association of aspirin with hepatocellular carcinoma and liver-related mortality.N Engl J Med2020;382:1018-28 PMCID:PMC7317648

[58] Krenkel O,Abdallah AT.Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.Gut2020;69:551-63

[59] Ponziani FR,Castelli C.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease.Hepatology2019;69:107-20

[60] Zhou J,Sinha RA,Yen PM.Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.Hepatoma Res2021;7:11 PMCID:PMC7116620

[61] Behary J,Jiang XT.Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.Nat Commun2021;12:187 PMCID:PMC7794332

[62] Conde de la Rosa L,Vallejo C.STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.J Hepatol2021;74:1429-41 PMCID:PMC8573791

[63] Marra F.Lipotoxicity and the gut-liver axis in NASH pathogenesis.J Hepatol2018;68:280-95

[64] Pinyol R,Wang H.Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.J Hepatol2021;75:865-78

[65] Paradis V,Mebarki M.Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome.Gut2013;62:911-9

[66] Wang B,Hu W,Din Y.Silencing of lncRNA SNHG20 delays the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma via regulating liver Kupffer cells polarization.IUBMB Life2019;71:1952-61

[67] Tian Y,Makiuchi S.Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas.J Cancer Res Clin Oncol2020;146:2461-77 PMCID:PMC7467955

[68] Rietman A,Feskens EJM,Mensink M.Associations between dietary factors and markers of NAFLD in a general Dutch adult population.Eur J Clin Nutr2018;72:117-23

[69] Kohli R,Xanthakos SA.High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.Hepatology2010;52:934-44 PMCID:PMC2932817

[70] Charlton M,Viker K.Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.Am J Physiol Gastrointest Liver Physiol2011;301:G825-34 PMCID:PMC3220319

[71] Dowman JK,Reynolds GM.Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.Am J Pathol2014;184:1550-61 PMCID:PMC4005975

[72] Harris SE,Arvaniti A,Gathercole LL.The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Am J Physiol Gastrointest Liver Physiol2020;319:G345-60 PMCID:PMC7509261

[73] Wolf MJ,Piotrowitz K.Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.Cancer Cell2014;26:549-64

[74] Wei G,Vaid KA.Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.Am J Physiol Gastrointest Liver Physiol2020;318:G174-88 PMCID:PMC6985845

[75] Fujii M,Wakamatsu K.A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.Med Mol Morphol2013;46:141-52

[76] Santhekadur PK,Sanyal AJ.Preclinical models of non-alcoholic fatty liver disease.J Hepatol2018;68:230-7 PMCID:PMC5775040

[77] Tsuchida T,Fujiwara N.A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.J Hepatol2018;69:385-95 PMCID:PMC6054570

[78] Asgharpour A,Pacana T.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.J Hepatol2016;65:579-88 PMCID:PMC5012902

[79] Nakagawa H,Taniguchi K.ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development.Cancer Cell2014;26:331-43 PMCID:PMC4165611

[80] Umemura A,Taniguchi K.p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells.Cancer Cell2016;29:935-48 PMCID:PMC4907799

[81] Bissig-Choisat B,Zorman B.A human liver chimeric mouse model for non-alcoholic fatty liver disease.JHEP Rep2021;3:100281 PMCID:PMC8138774

[82] Yoshioka N,Ochi K.The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.Biomed Pharmacother2021;140:111738

[83] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[84] Younes R,Govaere O.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.J Hepatol2021;75:786-94

[85] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[86] Dongiovanni P,Pietrelli A.Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.J Intern Med2018;283:356-70 PMCID:PMC5900872

[87] Gellert-Kristensen H,Davey Smith G,Tybjaerg-Hansen A.Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population.Hepatology2020;72:845-56

[88] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554